Aberrant splicing and drug resistance in AML

The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events have been recognized as a prominent component of this disease....

Descripción completa

Detalles Bibliográficos
Autores principales: de Necochea-Campion, Rosalia, Shouse, Geoffrey P., Zhou, Qi, Mirshahidi, Saied, Chen, Chien-Shing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018179/
https://www.ncbi.nlm.nih.gov/pubmed/27613060
http://dx.doi.org/10.1186/s13045-016-0315-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018179/
https://www.ncbi.nlm.nih.gov/pubmed/27613060
http://dx.doi.org/10.1186/s13045-016-0315-9

Ejemplares similares